Riociguat, a soluble guanylate cyclase (sGC) stimulator, was approved for treatment of chronic thromboembolic pulmonary hypertension (CTEPH) in 2013 and pulmonary arterial hypertension (PAH) in 2015. Here, SGCB is linked to pulmonary arterial hypertension.